Try our beta test site
Trial record 25 of 350 for:    hepatitis b | Open Studies

Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Corporacion Parc Tauli
Hospital Mutua de Terrassa
Consorci Sanitari de Terrassa
Information provided by (Responsible Party):
Mireia Miquel-Planas, Corporacion Parc Tauli Identifier:
First received: September 8, 2015
Last updated: September 10, 2015
Last verified: September 2015
The aim of this study is to evaluate the prevalence of hepatitis B in Vallés Occidental. Also, describe the stage of the disease, and whether if they are under medical treatment or not.

Condition Intervention
Hepatitis B
Other: Not apply

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study

Resource links provided by NLM:

Further study details as provided by Corporacion Parc Tauli:

Primary Outcome Measures:
  • prevalence hepatitis B [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • stage of the disease and if they are in treatment or not [ Time Frame: 1 day ]

Estimated Enrollment: 450
Study Start Date: July 2015
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Not apply
    None. Just registration epidemiology dates
Detailed Description:

The hepatitis B virus ( HBV ) is a global health problem . It is estimated that in the world there are about 350-400 million carriers of HBV surface antigen ( HBsAg ) 1 .

The prevalence in Spain is estimated at a 2-7 % and is considered a second intermediate prevalence.

For over 20 years, has carried out a program of primary prevention through universal vaccination against hepatitis B including it in the childhood vaccination schedule and has already been observed that in some estudi3 the prevalence has declined . For this reason , we want to evaluate what is the currently prevalence in our area of influence. There aren't recent studies to assess what is the current status of these patients ( how many , what risk factors which needs of treatment and with answer ...)


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The are Included consecutively for one year ( 1 June 2014 to 31 May 2015 ) all patients who are in the inclusion criteria

Inclusion Criteria:

  • Patients with HBsAg + visited in Digestive/Hepatology outpatient visits and Hepatology of the participating hospitals

Exclusion Criteria:

  • Patients < 18 aged
  • Duplicity on record
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02548325

Contact: Mireia Miquel, PhD +34937231010 ext 29805

Mútua de Terrassa Recruiting
Terrassa, Barcelona, Spain
Contact: PENDING         
Sponsors and Collaborators
Corporacion Parc Tauli
Hospital Mutua de Terrassa
Consorci Sanitari de Terrassa
  More Information

Responsible Party: Mireia Miquel-Planas, phD, Corporacion Parc Tauli Identifier: NCT02548325     History of Changes
Other Study ID Numbers: CorporacionPT
Study First Received: September 8, 2015
Last Updated: September 10, 2015

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections processed this record on March 24, 2017